CG Oncology (CGON) Stock: Buy, Sell, or Hold?
CGON - CG Oncology, Inc. Common stock
$72.35
0.35 (0.49%)
▲
5d:
-2.66%
30d:
-6.03%
90d:
+25.52%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 14, 2026
0d
Get Alerted When CGON Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: CGON shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: CGON shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: CGON is currently trading at $72.35, which is considered oversold relative to its 30-day fair value range of $72.75 to $78.14.
Technical Outlook: Technically, CGON is in a uptrend. Immediate support is located at $70.00, while resistance sits at $79.23.
Market Sentiment: CGON scores 24/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (15th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $91.08 (+25.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CGON is in a uptrend. Immediate support is located at $70.00, while resistance sits at $79.23.
Market Sentiment: CGON scores 24/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (15th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $91.08 (+25.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$72.75 -
$78.14
Company Quality Score
46/100
(HOLD)
Options IV Signal
15th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
66.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 15th percentile)
- BEARISH: Weak technical setup (24/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 25.9% below Wall St target ($91.08)
- WARNING: Composite score 46/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$72.75 -
$78.14
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$6.90
(9.5%)
Support & Resistance Levels
Support Level
$70.00
Resistance Level
$79.23
Current Trend
Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-23.95
Wall Street Target
$91.08
(+25.9%)
Revenue Growth (YoY)
1982.7%
Share & Embed Analysis
Last updated: September 11, 2026 9:11 PM ET
Data refreshes hourly during market hours. Next update: 10:11 PM
Data refreshes hourly during market hours. Next update: 10:11 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CGON showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
James Mulay
SELL
15600 shares
2026-04-17
James Mulay
SELL
1964 shares
2026-03-16
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$49 | 44 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1180 | 43 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 34 SELL |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$135 | 47 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 39 SELL |
